<DOC>
	<DOCNO>NCT02939651</DOCNO>
	<brief_summary>The purpose research study test pembrolizumab safe effective treating patient metastatic high-grade neuroendocrine tumor fail platinum base chemotherapy.The study drug , pembrolizumab FDA approve treat type skin cancer call melanoma metastatic non-small cell lung cancer . However , approve treatment metastatic high-grade neuroendocrine tumor .</brief_summary>
	<brief_title>A Study Pembrolizumab Patients With Neuroendocrine Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>1 . Patients must histologically cytologically confirm metastatic , high grade NET ( Ki67 &gt; 20 % ) , exclude high grade NETs large small cell type lung/thymus origin merkel cell carcinoma 2 . Patients must measurable disease , define least one lesion accurately measure least one dimension accordance RECIST criterion v. 1.1 described detail section 12.0 3 . Has receive prior therapy least 1 platinumcontaining regimen 4 . Age &gt; 18 year . 5 . ECOG performance status 0 1 6 . Patients must normal organ marrow function 7 . Female participant childbearing potential must negative serum pregnancy within 72 hour prior receive first dose study medication ) . They also willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study medication . Note : Abstinence acceptable usual lifestyle prefer contraception subject . 8 . Male participant must agree use adequate method contraception start first dose study therapy 120 day last dose study therapy Note : Abstinence acceptable usual lifestyle prefer contraception subject . 9 . Ability understand willingness sign write informed consent HIPAA consent document 1 . Known active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Subjects previously treat brain metastasis may participate provide stable ( without evidence progression image least four week prior first dose trial treatment neurologic symptom return baseline ) , evidence new enlarge brain metastasis , use steroid least 7 day prior trial treatment . This exception include carcinomatous meningitis exclude regardless clinical stability . 2 . Is currently participate receive study therapy participate study investigational agent receive study therapy use investigational device within 4 week first dose treatment . 3 . Diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment . 4 . Prior anticancer therapy monoclonal antibody ( mAb ) within 4 week prior study Day 1 recover adverse event ( improve grade 1 less ) due mAbs administer 4 week earlier . 5 . Prior chemotherapy , target small molecule therapy , radiation therapy within 2 week ( 12 week measurable site CNS disease ) prior study Day 1 recover adverse event ( improve grade 1 less ) due previously administer agent . Note : Subjects neuropathy â‰¤ Grade 2 alopecia exception criterion may qualify study . Note : If subject receive major surgery , must recover adequately toxicity and/or complication intervention prior start therapy . 6 . Known additional malignancy progress require active treatment except superficial malignancy skin situ cervical cancer 7 . Has active autoimmune disease require systemic treatment past 2 year ( i.e . use disease modify agent , corticosteroid immunosuppressive drug ) . Replacement therapy ( e.g. , thyroxine , insulin , physiologic corticosteroid replacement therapy adrenal pituitary insufficiency , etc . ) consider form systemic treatment . 8 . Has history ( noninfectious ) pneumonitis require steroid , evidence interstitial lung disease active noninfectious pneumonitis . 9 . Active infection require systemic therapy enrollment . 10 . Has know history active TB ( Bacillus Tuberculosis ) 11 . Hypersensitivity pembrolizumab excipients 12 . Has receive live virus vaccine within 30 day plan start trial treatment . 13 . Pregnant , breastfeeding , expect conceive father child within project duration trial , start screen period 120 day last dose trial treatment 14 . Prior therapy antiprogrammed cell death 1 ( PD1 ) , antiprogrammed cell death 1 ligand ( PDL1 ) , antiPDL2 , agent direct another coinhibitory Tcell receptor ( e.g . CTLA4 , OX40 , CD137 ) 15 . Known history human immunodeficiency virus ( HIV ) 16 . Known active Hepatitis B ( e.g. , HBsAg reactive ) Hepatitis C ( e.g. , HCV RNA [ qualitative ] ) . 17 . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial 18 . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Metastatic</keyword>
	<keyword>High grade</keyword>
</DOC>